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Macrophages are the epicenter of all immune systems (1). The first
and the most abundant leukocyte observed (2), macrophage have
long been relegated to the role of “servants”of T or B cells/adaptive
immunity. This view is now known to be backward. Macrophages
necessarily initiate and direct virtually all immune responses from
simple multicellular animals to humans.
There is good news and bad news in the newly recognized
importance of macrophages/innate immunity. The well-known
“double-edged sword” nature of the immune system can largely be
attributed to macrophages’ unique ability to make polar-opposite
repair/heal (M2) or kill/inhibit (M1) type responses (3).
In health, M2-type macrophages maintain homeostasis by
helping repair and replace lost or effete cells. Ever-present in
tissues, macrophages are also the primary host defense against
pathogens (or altered self cells) because their unique physiol-
ogy allows them to rapidly switch from their M2/heal mode to
an M1/inhibit mode: both powerful responses; both potentially
dangerous.
In disease, over expression of M2/heal macrophages contributes
to chronic infections, fibrosis, allergy, and cancer (3). Conversely,
M1/inhibit-dominant activity plays a major role in atherosclerosis,
autoimmunity, and other chronic inflammatory conditions.
Of fundamental importance is that both the routine M2/heal
and the induced M1/inhibit macrophage functions occur in all
animals whether they have T cells or not. Furthermore, M1 and
M2 macrophage responses play necessary roles in causing T cells
to make Th1 or Th2-type responses if pathogens or altered self are
present (4). Hence, the renaming of macrophage responses M1
and M2.
This new knowledge about the central role of macrophages
in immune systems brings great promise for increasing health/
decreasing disease. In this regard, the ability of macrophages to
exhibit the polar-opposite M2/heal and M1/kill functions result, in
part, from their unique ability to metabolize one amino acid – argi-
nine – to either growth-promoting ornithine or growth-inhibiting
nitric oxide (NO) (5). Hence, the title of this Topic, “M1 and M2
Macrophages: The Arginine Fork in the Road to Health and Dis-
ease.” We hope that the articles assembled here help illuminate
the basic functions of macrophages referred to as SHIP [sample,
heal, inhibit, and present (antigen)]. Such knowledge is criti-
cal for developing the means to modulate the direct M2/heal or
M1/inhibit responses of macrophages, or their indirect abilities to
initiate and direct T and B cell responses. One can properly say
macrophages are the “chicken and the egg” of immunity (1).
ORIGIN OF M1/INHIBIT AND M2/HEAL MACROPHAGES AND
THE SCOPE OF THE TOPIC
As an introduction to M1 and M2 macrophages, a chronology of
results (and publications) that led to their discovery is summarized
below:
• Macrophages have the unique ability to produce a growth-
inhibiting molecule (NO) or a growth-promoting molecule
(ornithine), through the enzymatic conversion of l-arginine in
different ways (6–8).
• Macrophages in normal tissues, healing wounds, or in growing
tumors metabolize arginine primarily to ornithine via arginase
(later to be named M2-type). Macrophages can switch to pro-
ducing NO via iNOS (to be named M1-type) that is necessary
to kill cancer or many pathogens. Arginine is the source of both
ornithine and NO (9–12).
• Macrophages were specifically renamed M1 and M2 to highlight
that innate immunity controls adaptive immunity. M1 (NO)
or M2 (ornithine)-type macrophage responses are T cell inde-
pendent and they stimulate Th1-type and CTL responses, or
Th2-type responses, respectively (1, 3–5). Thus, M1/M2 rep-
resents a sea change in our understanding of how immune
responses occur.
These studies have stimulated thousands of publications that
have enhanced our knowledge of the importance of M1/inhibit
and M2/heal functions, and other cytokines and factors that
accompany these responses (1). Here, we have assembled papers
by contributors that focus on basic aspects of macrophage biol-
ogy, their roles in various diseases, and how they are regulated.
Macrophages evolved long before other immune cell types and
are the foundation of all animal immunity (13). Therefore, we
begin with a series of “introductory” articles where readers can
find basic information about macrophage biology and functions.
These articles also trace the evolutionary origins of macrophages
to aid in understanding their central role in immune systems. Next,
articles detail the roles of macrophages in protection against (or
causation of) various diseases including wounds, cancer, infec-
tions, atherosclerosis, obesity, hypertension, and other conditions.
Finally, we look to the future with several articles detailing how
macrophage M1/inhibit and M2/heal functions might be modu-
lated for therapeutic benefits. We hope that the articles enhance
your knowledge of this singularly multitalented and remarkable
leukocyte.
www.frontiersin.org February 2015 | Volume 6 | Article 59 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mills et al. Summary of M1/M2 macrophages topic
INTRODUCTION TO MACROPHAGE BIOLOGY AND
FUNCTIONS
To better appreciate macrophages, it is useful to known about their
unique biochemistry, functions, and central role in all immune
systems. Drs. Rath and Munder provide a comprehensive bio-
chemical introduction to macrophage arginine metabolism, and
how these cells can take “the fork in the road” to make either
an arginine-based M1/inhibit or M2/heal response (14). Because
“Nothing makes sense except in the light of evolution” (Theodo-
sius Dobzhansky), Dr. Buchmann traces the evolutionary origins
of both innate and adaptive immunity, and shows when new
macrophage (and other) immune functions evolved, culminating
in humans (15). Dr. Dzik importantly reveals that the macrophage
M2/heal function (arginases) preceded the M1/inhibit function
in animal evolution (16). Drs. Mills, Thomas, Lenz, and Munder
describe the basic “SHIP” functions of macrophages [sample, heal,
inhibit, and present (antigen)], and why it is important to study
these functions to understand macrophage biology in vivo (17). In
a similar vein, Drs. Italiani and Boraschi elucidate why examining
macrophages by functions versus “phenotypes” can be critical for
understanding how they affect health (18). Dr. Harris’ piece col-
orfully describes the two-edged sword nature of macrophages as
“The Good the Bad and the Ugly” phases of inflammation. He also
illuminates that M1/inhibit or M2/heal-type macrophage activi-
ties vary enormously in different microenvironments of lungs or
other sites of inflammation (19). In turn, important local func-
tions can be lost if one grinds up whole organs as is common. Drs.
Thomas and Mattila provide an in-depth look at macrophage argi-
nine metabolism in different vertebrate species (20). Importantly,
they show that, contrary to some reports (21, 22), macrophages
in mice and humans are quite similar, as one might expect from
analyzing evolution (e.g., Drs. Buchmann and Dzik, mentioned
earlier).
MACROPHAGE INFLUENCES IN DIFFERENT DISEASES
WOUNDS AND CANCER: STARK EXAMPLES OF THE TWO-EDGED
SWORD NATURE OF MACROPHAGE RESPONSES
Wound healing requires M2/heal-type responses (9). If M1/inhibit
responses occur (e.g., infected wounds) wound healing is delayed
until the infection is cleared (5). M2/heal-type macrophages also
dominate inside tumors in experimental animals and humans (5,
11, 23). In marked contrast to their beneficial effect in wounds,
M2-type macrophages actively promote tumor growth [reviewed
in Ref. (3)], in part, by secreting growth factors (11, 24, 25).
Regarding the relative roles of M1 or M2-type macrophages
in wounds or implanted biomaterials, Drs. Brown, Sicari, and
Badylak demonstrate that there is 2–3 day dominance of M1-type
macrophages (26). These data support that the first biologic prior-
ity of hosts following injuries is to prevent infections (5). However,
if an injury is sterile, the priority switches to M2-type dominant
macrophages that are necessary for proper healing (17). Inter-
estingly, they note that biomaterials with larger pore sizes have
less scarring/fibrosis. Thus, the physical properties of implanted
materials seem important in allowing functional regeneration
over typical imperfect wound healing found in adult humans
(27). Drs. Beljaars, Schippers, Smit, Martinez, Helming, Poelstra,
and Melgert compared M1- and M2-types of macrophages inside
chemically damaged livers in mice and cirrhotic livers in humans
(28). The liver is one of the few organs able to regenerate (though
not perfectly) (29). So, it was interesting that they found a predom-
inance of M1 macrophages during resolution of damage, which
contrasts with M2 macrophages that dominate in wounds else-
where, and which results in scarring/healing, as described. Also,
interesting was that the authors observed distinct M1 and M2-
type macrophages in close proximity to each other with little
overlap in markers. These findings do not support the hypoth-
esis that macrophages only resemble a “color wheel” with multiple
overlapping characteristics (30).
In contrast to the beneficial effects of M2-type macrophages in
wounds, these same types of macrophages promote cancer growth
and metastases as mentioned [reviewed in Ref. (3)]. Why is there
cancer, and why does the immune system help it grow?
Species successfully evolve by acquiring traits that provide sur-
vival advantages, and losing undesirable traits. Environmental and
societal influences aside, the way animals (any species) change
heritable traits is through producing progeny: breeding. Can-
cer in humans occurs mainly after breeding age. So, there has
been little evolutionary pressure (or advantage) for humans to
acquire traits that prevent cancer, or that could stop it if it appears.
The same lack of evolutionary pressure applies to atherosclerosis,
or many other “adult” diseases that mainly occur during post-
breeding (to be discussed later). Too, mate selection (important in
breeding success) is mostly unaffected by knowledge of whether
parents or grandparents died of cancer or other late-appearing
diseases (3).
Once it appears, cancer can be eliminated. How? Modulat-
ing macrophage functions. It is now known that the major-
ity leukocytes in tumors are macrophages: sometimes >50% of
a tumor mass. However, as mentioned, these tumor-associated
macrophages (TAM) are primarily M2-type and actively pro-
mote tumor growth: Cancer is often referred to as “a wound
that doesn’t heal” (31). But, a wealth of recent evidence indi-
cates that decreasing M2/heal-type and increasing M1/inhibit-
type macrophages can slow or reverse tumor growth (11, 32).
This is an exciting development because conventional immuno-
logic thinking purports that tumors need to be recognized as
“foreign,” like a pathogen. But, most tumors are not “foreign.”
So, it falls on the shoulders of innate immunity, not adaptive
immunity (T and B cells), to stop cancer. Importantly, recent
antitumor effects being observed seem primarily (or solely) medi-
ated by macrophages/innate immunity, not T cells (32). Even if
a human cancer is recognized as “foreign,” it is still critical to
switch M2- to M1-like macrophages. This is so because of the
new knowledge, discussed earlier, that M1-type macrophages are
necessary to stimulate T cells to make tumoricidal Th1-type cel-
lular killer responses such as CTL and further amplify M1/inhibit
macrophages (1, 4). In a related connection, significant prolon-
gation of survival in human cancer has recently been observed by
inhibiting immunoregulatory molecules, such as PD-1 and CTLA4
(33). The effects observed have been postulated to involve specific
anti tumor T cell activity. Such effects likely depend on modulat-
ing macrophage responses. Thus, increasing our knowledge of M1
and M2 polarization in cancer, and how to modulate it, is very
important.
Frontiers in Immunology | Molecular Innate Immunity February 2015 | Volume 6 | Article 59 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mills et al. Summary of M1/M2 macrophages topic
Drs. Laoui, Van Overmeire, Baetselier, Van Ginderachter, and
Raes review the evidence that M2-type macrophages predominate
in most human tumors with the notable exception of colorec-
tal cancer (34). They also describe new evidence that colony-
stimulating factors are important players in determining the quan-
tity and type of macrophages that populate tumors. MCSF is
normally present in tissues and plasma, and is associated with
M2-type macrophages. In contrast, GM-CSF is only present fol-
lowing injury or during infections, and is associated with M1-type
responses. Interestingly, the authors highlight findings suggest-
ing inhibition of MCSF by various means in humans does not
only simply decrease M2-type TAM but also increases the M1/M2
ratio. Thus, altering macrophage differentiation signals can affect
macrophage polarization beneficially in clinical settings. Using a
different approach, Drs. Fritz, Tennis, Orlicky, Lin, Ju, Redente,
Choo, Staab, Bouchard, Merrick, Malkinson, and Dwyer-Nield
show that treatment of lung cancer in mice with a macrophage-
depleting agent (clodronate-encapsulated liposomes) significantly
decreases tumor burden (35). They also show that this treat-
ment stimulates lung TAM that have a mixed M1- and M2-type
phenotype suggesting that this depletion modality (like MCSF
inhibition) may also increase the M1/M2 TAM balance. Together,
these studies, like many others, are indicating that there are real and
important clinical benefits from immunologically manipulating
macrophage functions in cancer.
MACROPHAGES IN INFECTIONS
In the context of animal models of bacterial infection, M1-type
macrophages and NO production are often, but not exclusively
(36), associated with host protection (17). Conversely, M2-type
macrophages are typically associated with bacterial persistence.
An article by Drs. Ka, Daumas, Textoris, and Mege reviews
macrophage polarization in infectious diseases (37). They dis-
cuss some difficulties encountered when trying to extend these
concepts to bacterial infections in humans. In humans suffer-
ing from leprosy or Whipple’s, macrophage, M2-type polarization
can be readily observed. However, as mentioned earlier, analyz-
ing whole organs can overlook microenvironmental differences
in inflammation (19). Also, studies with human patients often
utilize peripheral blood monocytes that lack the polarized M1-
or M2-type functions associated with tissue macrophages. They
also review that many pathogens, such as Leishmania, can survive
or spread by blocking or subverting the process of macrophage
development toward an M1/inhibit phenotype (27). An article
from Drs. Burrack and Morrison discusses how macrophage acti-
vation and arginine metabolism by M1- or M2-type macrophages
can have diverse effects on health and disease during viral infec-
tions (38). Macrophage NO production during viral infections,
as in other settings, can be induced independent of lymphocytes
(4). The production of NO can have direct anti-microbial effects
on certain bacteria, fungi, and viruses. Hence, the M1/inhibit
phenotype in these settings plays an immune protective role.
However, because NO kills non-specifically, it can also have
immunopathologic or immune suppressive effects during infec-
tions by influenza, herpes simplex virus-1, and cytomegalovirus.
Similarly, the two-edged sword nature of M2/heal macrophage
responses can cut both ways. For example, M2/heal responses
(via arginase and growth-promoting ornithine) usefully promote
tissue repair in some viral infection models, and via stimulat-
ing protective antibody responses. However, M2/heal responses
are also associated with viral persistence or immune pathol-
ogy during many infections, such as coronavirus-induced sudden
acute respiratory syndrome (SARS), hepatitis B or C viruses,
Ross river virus, HIV, and influenza. These articles indicate
that it is important to understand the infectious disease type,
stage, and severity in order to properly modulate M1- or M2-
type responses to optimally eliminate pathogens and decrease
untoward pathology.
MACROPHAGE RESPONSES IN ATHEROSCLEROSIS AND OTHER
NON-PATHOGEN-INDUCED INFLAMMATORY CONDITIONS
In contrast to the primarily protective role of M1/inhibit-
type responses against infection agents, described above, these
killer/damaging activities are often associated with bad outcomes
in chronic inflammatory conditions.
Regarding atherosclerosis, Drs. Thomas and Mattila show that
both M1- and M2-types of macrophages are found during foam
cell formation, a hallmark of atherosclerosis (20). Drs. Hayes,
Tsaousi, Gregoli, Jenkinson, Bond, Johnson, Bevan, Thomas, and
Newby show that there is an altered expression of certain matrix
metalloproteinases in atherosclerosis (39). Interestingly, they also
show that M1 and M2 macrophage polarization in atherosclerotic
ApoE null mice occurs in the absence of T- and B-lymphocytes,
again highlighting the independence of innate immunity from
adaptive immunity discussed earlier. Drs. Murphy, Dragoljevic,
and Tall review the recent evidence that cholesterol efflux pathways
regulate myelopoiesis (40). Traditionally, cholesterol efflux was
considered as a safeguard against foam cell formation, but Tall’s
group has shown that knocking out cholesterol efflux molecules
like ABCA1 and ABCG1 cause profound changes in hematopoiesis
associated with more Ly6C+ inflammatory monocytes and more
neutrophils. This shift could lead to altered macrophage func-
tion. Drs. Peled and Fisher review dynamic aspects of macrophage
polarization during atherosclerosis progression and regression:
progression is associated with macrophage M1 polarization and
regression with M2 polarization (41). The article by Drs. Yang
and Ming looks at the less commonly studied arginase II enzyme.
They show that, unlike arginase I, that is typically inversely
related to macrophage NO production, arginase II seems under
different regulation. Also, Arg II expression in endothelial cells
tends to uncouple eNOS (or NOS1) causing loss of vascular
tone (42).
Regarding other non-pathogen associated inflammatory con-
ditions, Drs. Vlahos and Bozinovski review the role of alveolar
macrophages in chronic obstructive pulmonary disease (COPD)
(43). COPD is a widespread chronic inflammatory condition
with immense medical and societal impact. Interestingly, in
COPD, there is an accumulation of airway macrophages that
show a transcriptome skewed toward wound healing M2 mark-
ers suggesting defective resolution of inflammation (as occurs
in wound healing). Drs. Kraakman, Murphy, Jandeleit-Dahm,
and Kammoun review macrophage polarization in obesity and
type 2 diabetes (44). M1 “pro-inflammatory” macrophages are
enhanced compared with M2 “anti-inflammatory” macrophages,
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leading to chronic inflammation and the propagation of metabolic
dysfunctions. The brain and spinal cord are primarily populated by
macrophage-like microglial cells, which are derived from yolk sac
precursors under resting conditions. Drs. Cherry, Olschowka, and
O’Banion show that these microglia are normally M2-polarized,
although the microglia transcriptome is different from that of
M2 macrophages in other organs (45). This observation fits
well with an emerging concept that M1 and M2 polarization
varies between organs (46). In this connection, Drs. Brown,
von Chamier, Allam, and Reyes report on M1/M2 macrophage
polarity in normal and complicated pregnancies and find that
the balance and location of M1- and M2-type responses show
significant variation (47). In general, over expression of M1-
type macrophages is associated with untoward outcomes during
pregnancy.
Finally, this Topic focuses on macrophage polarization. Little
is currently known about how the origin of macrophages in tis-
sues (e.g., yolk sac, Ly6C-high, Ly-6C-low monocytes) influence
M1/M2 polarization. Drs. Dey, Allen, and Hankey-Giblin begin
to explore how the ontogeny of monocytes and macrophage can
influence M1- and M2-type responses in different tissues (48).
REGULATION OF MACROPHAGE DIFFERENTIATION AND
FUNCTIONS
The importance of macrophage M1/inhibit and M2/heal imbal-
ances in various disease or protective processes being clear,
immunologists and clinicians are interested in how they might
therapeutically intervene to shape macrophage differentiation or
modulate various macrophage functions to restore health. Drs.
Wang, Liang, and Zen provide an overview of the various molecu-
lar mechanisms known to impact macrophage M1 and M2 polar-
ization (49). Several of these mechanisms are expanded upon in
subsequent articles. Cytokines such as interferon gamma (IFN-γ)
have profound impacts on development of M1 and M2 functional-
ity in macrophages. Regulators of cytokine receptor signaling can
importantly impact macrophage functions. Dr. Wilson details in
her article evidence that various suppressor of cytokine signaling
(SOCS) protein family members shape M1/M2 macrophage func-
tions in several disease settings (50). Colony-stimulating factors
(CSFs) and macrophage stimulating protein (MSP) also impact
macrophage responsiveness to polarization. Drs. Hamilton, Zhao,
Pavicic, and Datta introduce the concept that the myeloid colony-
stimulating factors MCSF and GM-CSF act not only to promote
the development and maintenance of various myeloid populations
but can also shape the responsiveness of macrophages to stimuli
that direct the M1 or M2 phenotype (51). The effects of MSP
and its receptor, a tyrosine kinase known as RON, on macrophage
polarization are clearly presented in an article by Dr. Chaudhuri
(52). Other extrinsic factors that regulate macrophage polariza-
tion include components of the complement cascade as well as
extracellular nucleotides. The contrasting effects of various com-
plement components on M1 and M2 functions are described in
an article by Drs. Bohlson O’Conner, Hulsebus, Ho, and Fraser
(53). Drs. Desai and Leitinger go on to detail how purinergic
receptors for extracellular ATP and other nucleotides couple with
calcium signaling to modulate macrophage activities and reso-
lution of inflammation (54). An improved understanding of how
these extrinsic factors and intrinsic signaling pathways regulate the
acquisition of M1 and M2-type functions will lead to improved
methods for fine-tuning of macrophage polarization to promote
health.
As mentioned above, a key difference between M1 and M2
macrophages is in their processing of l-arginine. NO can not only
kill susceptible microbes but also has a variety of signaling and
regulatory effects on macrophages and other cell types. NO is
generated from l-arginine through the activities of three NO syn-
thase (NOS) enzymes. In contrast to canonical views, Drs. Mattila
and Thomas present the perspective that “constitutive” enzyme
activities (NOS1 and 3) can be induced, and “inducible” NOS2 is
constitutively expressed in several tissues (55). The different func-
tions of M1 and M2 macrophages are also associated with changes
in the metabolic pathways they use to produce ATP. Drs. Galván-
Peña and O’Neill discuss the differences in metabolism between
M1 and M2 macrophages and how these differences impact other
aspects of macrophage function (56). M1 macrophages mainly
rely on glycolysis for energy, while M2 macrophages primarily
use oxidative phosphorylation. Accumulation of succinate in M1
macrophages can stimulate HIF1α to sustain production of factors
such as IL-1β and thus can impact the ability of M1 macrophages
to prolong inflammation. Manipulation of NOS enzyme expres-
sion and activities as well as the products and consequences of the
different metabolic processes in M1 and M2 macrophages should
further our ability to shape the outcome of infections and other
diseases.
SUMMARY
The “Fork in the Road” that macrophages take in making
either M1/inhibit or M2/heal-type responses define “immunity”
throughout the animal kingdom. In all animals, M1/inhibit-
type responses are the primary host defense, and M2/heal-type
responses help repair and replace lost or effete tissue to main-
tain host homeostasis. In humans (and other higher animals),
macrophage M1/inhibit or M2/heal-type responses necessarily
direct T (and B) cells/adaptive immunity to make Th1 or Th2-
like responses. Thus, whether acting directly or indirectly, which
“fork” macrophages take is the central controlling element that
promotes health (as in pathogen control or wound repair) or
impedes health (as in atherosclerosis, autoimmunity, or cancer).
By illuminating the biochemical underpinnings, evolution, dis-
eases, and regulation of macrophage functions, the papers in
this Topic advance our understanding of how to modulate this
most important of all leukocytes: the chicken and the egg of
immunity (1).
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